Breaking policy and perceptual barriers: BiosimilarsExperts from Research Partnership analyse the company’s Therapy Watch data to identify how market access policy has impacted Share XBreaking policy and perceptual barriers: Biosimilarshttps://deep-dive.pharmaphorum.com/magazine/market-access-2020/breaking-policy-and-perceptual-barriers-biosimilars/
The promise and pitfalls of molecular testing in oncologyGreat strides have been made in the diagnosis and treatment of cancer. However, a variety of challenges remain Share XThe promise and pitfalls of molecular testing in oncologyhttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/research-partnership-molecular-testing-cancer/
China in the fast laneBrett Gardiner and Boon Yap from Research Partnership discuss access opportunities for novel therapies in the world’s hottest Share XChina in the fast lanehttps://deep-dive.pharmaphorum.com/magazine/access-and-commercialisation/research-partnership-pharma-market-access-china/
Deep Dive: Access and CommercialisationIn this issue of Deep Dive we explore the ever present issues of market access and commercialisation, analysing Share XDeep Dive: Access and Commercialisationhttps://pharmaphorum.com/digital/pharma-access-commercialisation/
Navigating new frontiers: Ways to find space in the future RA marketOverview Rheumatoid arthritis (RA) has been a major growth driver for the pharmaceutical industry over the last 15 Share XNavigating new frontiers: Ways to find space in the future RA markethttps://pharmaphorum.com/r-d/navigating-new-frontiers-ways-to-find-space-in-the-future-ra-market/
Are dual ARVs the new frontier in a maturing HIV market?Tackling and managing HIV has been one of the pharmaceutical industry’s more distinguished achievements, despite the turbulence and Share XAre dual ARVs the new frontier in a maturing HIV market?https://pharmaphorum.com/sales-marketing/are-dual-arvs-the-new-frontier-in-a-maturing-hiv-market/
